The FDA approved Cyltezo, a second biosimilar for AbbVie's Humira, Medscape reports.
Here's what you should know:
1. The FDA approved the first biosimilar, adalimumab-atto, in September 2016.
2. Cyltezo is approved to treat several diseases including: rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and plaque psoriasis.
3. Cyltezo is a tumor necrosis factor blocker.
4. Adverse events associated with adalimumab-atto include infections and malignancies. The most common events, however, are infections and injection-site reactions.